Logos for IncyteCARES and PEMAZYRE pemigatinib (tablets).

IncyteCARES for PEMAZYRE is a program for residents of the United States and US territories.

For Healthcare Professionals Arrow

We’re Here to Support You During Treatment With PEMAZYRE

At IncyteCARES for PEMAZYRE, our team can help you understand your insurance coverage, explore financial assistance options, and provide as-needed support.

PEMAZYRE prescriptions are filled through Biologics by McKesson specialty pharmacy.

Biologics will work with you and your caregivers to help ensure you have support during treatment with PEMAZYRE.

IC Video Thumbnail Video play icon

Have you been prescribed PEMAZYRE?
See how our team can help!

Watch Video

For Eligible Patients, Our Team Can Provide:

  • Help with understanding your insurance coverage
  • Pharmacy outreach call when you start PEMAZYRE
  • Flexibly scheduled follow-up calls from a pharmacy care team specialist to fit your needs
  • Information about your medicine and condition
  • Text message refill reminders
  • Referrals to advocacy and support organizations
  • Financial assistance options

Financial Assistance and Savings Options for PEMAZYRE

Eligible patients can receive PEMAZYRE for as little as $0, subject to certain limits*

To qualify, you must:

  • Have commercial prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or a US territory
  • Have a valid prescription for PEMAZYRE for an FDA-approved use

*Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Valid prescription for PEMAZYRE® (pemigatinib) for an FDA-approved indication or compendia-recognized use is required. Please see the full Patient Terms and Conditions or call IncyteCARES for PEMAZYRE at 1-855-452-5234. Update effective as of January 1, 2024.

*Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Valid prescription for PEMAZYRE® (pemigatinib) for an FDA-approved indication or compendia-recognized use is required. Please see the full Patient Terms and Conditions or call IncyteCARES for PEMAZYRE at 1-855-452-5234. Update effective as of January 1, 2024.

To enroll, you can either:

  1. Call IncyteCARES for PEMAZYRE at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.
    A representative will ask a few questions. If you are eligible, your program information will be recorded so you can begin receiving PEMAZYRE for as little as $0 out-of-pocket cost.

  2. Ask your Healthcare Professional to enroll you in the Savings Program.

Eligible patients can receive PEMAZYRE free of charge†

The IncyteCARES for PEMAZYRE Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or who have trouble affording their out-of-pocket costs for PEMAZYRE. No purchase contingencies or other obligations apply.

To qualify, you must:

  • Be confirmed as eligible and enrolled in IncyteCARES for PEMAZYRE
  • Be a resident of the United States or a US territory
  • Have a valid prescription for PEMAZYRE for an FDA-approved use
  • Meet one of these 3 criteria:

Uninsured

    1. You have no prescription drug coverage and meet household income criteria

Underinsured‡

    1. You have no prescription drug coverage and meet household income criteria
    2. You have Medicare Part D and meet household income criteria
    3. You have any other type of prescription drug insurance (commercial, Medicaid, etc) but have exhausted or been denied coverage for PEMAZYRE and meet household income criteria

To apply, you can either:

  1. Call IncyteCARES for PEMAZYRE at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

    To start, we’ll ask you a few questions to help determine your eligibility for this program. Based on your answers, we will notify you within 2 business days if you qualify for conditional approval. That means you’re approved for a supply of free medicine for 90 days.

    In the meantime, you must send us proof of your current household income. It can be one of the following: your most recent federal income tax return, your most recent W-2 earnings statement from your employer, or one month of your recent pay stubs. Once we review your income information, we’ll notify you if you are fully approved for the IncyteCARES for PEMAZYRE Patient Assistance Program and can continue to receive PEMAZYRE for free.

  2. Ask your Healthcare Professional to submit an application form for you.

†Terms and conditions apply. Terms of this program may change at any time.

‡Patients who are enrolled in an Alternate Funding Program (AFP) are not eligible to receive free drug.

Eligible patients may be able to receive a free short-term supply of PEMAZYRE§

If you have been prescribed PEMAZYRE for an FDA-approved use and you experience a delay in coverage, we may be able to provide a free 30-day supply of medicine. To be eligible, you must submit a proof of insurance claim verifying the delay. Free product is offered to eligible patients without any purchase contingency or other obligation.

To qualify, you must:

  • Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or a US territory
  • Have a valid prescription for PEMAZYRE for an FDA-approved use
  • Provide proof of the submitted claim and coverage delay. This may be a notice you receive from your insurance company

§Terms and conditions apply. Terms of this program may change at any time.

To apply, you can either:

  1. Call IncyteCARES for PEMAZYRE at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

  2. Ask your Healthcare Professional to submit an application form for you.

phone support icon

Questions?

Call IncyteCARES for PEMAZYRE at 1-855-452-5234,
Monday through Friday, 8 AM–8 PM ET

INDICATIONS AND USAGE

PEMAZYRE is a prescription medicine that is used to treat adults with:

  • bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:
    • who have already received a previous treatment, and
    • whose tumor has a certain type of abnormal FGFR2 gene
  • a type of blood cancer called myeloid/lymphoid neoplasms (MLNs):
    • when it has come back or did not respond to treatment, and
    • whose tumor has a certain type of abnormal FGFR1 gene

Your healthcare provider will test your cancer for certain types of abnormal FGFR1 or FGFR2 genes and make sure that PEMAZYRE is right for you.

It is not known if PEMAZYRE is safe and effective in children.

PEMAZYRE is approved based on tumor response and duration of response. There are ongoing studies to show whether PEMAZYRE can improve survival or symptoms.

IMPORTANT SAFETY INFORMATION

Before you take PEMAZYRE, tell your healthcare provider about all of your medical conditions, including if you:

  • have vision or eye problems
  • have kidney problems
  • have liver problems
  • are pregnant or plan to become pregnant. PEMAZYRE can harm your unborn baby or cause loss of your pregnancy (miscarriage). You should not become pregnant during treatment with PEMAZYRE.

    Females who can become pregnant:

    • Your healthcare provider should do a pregnancy test before you start treatment with PEMAZYRE.
    • You should use an effective method of birth control during treatment and for 1 week after your last dose of PEMAZYRE. Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.

    Males with female partners who can become pregnant:

    • You should use effective birth control when sexually active during treatment with PEMAZYRE and for 1 week after your last dose of PEMAZYRE.
  • are breastfeeding or plan to breastfeed. It is not known if PEMAZYRE passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of PEMAZYRE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of PEMAZYRE?

PEMAZYRE may cause serious side effects, including:

  • Eye problems. Certain eye problems are common with PEMAZYRE but can also be serious. Eye problems include dry eye or inflamed eyes, inflamed cornea (front part of the eye), increased tears, and a disorder of the retina (an internal part of the eye). You will need to see an eye specialist for a complete eye exam before you begin treatment with PEMAZYRE, every 2 months for the first 6 months, and then every 3 months during treatment with PEMAZYRE.
    • You should use artificial tears or substitutes, hydrating or lubricating eye gels as needed, to help prevent or treat dry eyes.
    • Tell your healthcare provider right away if you develop any changes in your vision during treatment with PEMAZYRE, including: blurred vision, flashes of light, or see black spots. You may need to see an eye specialist right away.
  • High phosphate levels in your blood (hyperphosphatemia) and buildup of minerals in different tissues in your body. Hyperphosphatemia is common with PEMAZYRE but can also be serious. High levels of phosphate in your blood may lead to buildup of minerals such as calcium, in different tissues in your body. Your healthcare provider will check your blood phosphate levels during treatment with PEMAZYRE.
    • Your healthcare provider may prescribe changes in your diet or phosphate lowering therapy, or change, interrupt, or stop PEMAZYRE if needed.
    • Tell your healthcare provider right away if you develop any muscle cramps, or numbness or tingling around your mouth.

The most common side effects of PEMAZYRE for cholangiocarcinoma include:

  • hair loss
  • diarrhea
  • nails separate from the bed or poor formation of the nail
  • feeling tired
  • change in sense of taste
  • nausea
  • constipation
  • mouth sores
  • dry eyes
  • dry mouth
  • decrease in appetite
  • vomiting
  • joint pain
  • stomach-area (abdominal) pain
  • low phosphate in blood
  • back pain
  • dry skin

The most common side effects of PEMAZYRE for myeloid/lymphoid neoplasms (MLN) include:

  • nails separate from the bed or poor formation of the nail
  • hair loss
  • mouth sores
  • diarrhea
  • dry eyes
  • tiredness
  • anemia
  • stomach-area (abdominal) pain
  • rash
  • constipation
  • dry mouth
  • nose bleeds
  • disorder of the retina
  • pain in feet or hands
  • decrease in appetite
  • dry skin
  • indigestion
  • back pain
  • nausea
  • blurry vision
  • swelling in feet, legs, hands, or arms
  • dizziness

These are not all the possible side effects of PEMAZYRE. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Keep PEMAZYRE and all medicines out of the reach of children.

General information about the safe and effective use of PEMAZYRE.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PEMAZYRE for a condition for which it is not prescribed. Do not give PEMAZYRE to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.

Please see the Full Prescribing Information for PEMAZYRE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS AND USAGE

PEMAZYRE is a prescription medicine that is used to treat adults with:

  • bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:
    • who have already received a previous treatment, and
    • whose tumor has a certain type of abnormal FGFR2 gene
  • a type of blood cancer called myeloid/lymphoid neoplasms (MLNs):
    • when it has come back or did not respond to treatment, and
    • whose tumor has a certain type of abnormal FGFR1 gene

Your healthcare provider will test your cancer for certain types of abnormal FGFR1 or FGFR2 genes and make sure that PEMAZYRE is right for you.

It is not known if PEMAZYRE is safe and effective in children.

PEMAZYRE is approved based on tumor response and duration of response. There are ongoing studies to show whether PEMAZYRE can improve survival or symptoms.

IMPORTANT SAFETY INFORMATION

Before you take PEMAZYRE, tell your healthcare provider about all of your medical conditions, including if you:

  • have vision or eye problems
  • have kidney problems
  • have liver problems
  • are pregnant or plan to become pregnant. PEMAZYRE can harm your unborn baby or cause loss of your pregnancy (miscarriage). You should not become pregnant during treatment with PEMAZYRE.

    Females who can become pregnant:

    • Your healthcare provider should do a pregnancy test before you start treatment with PEMAZYRE.
    • You should use an effective method of birth control during treatment and for 1 week after your last dose of PEMAZYRE. Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.

    Males with female partners who can become pregnant:

    • You should use effective birth control when sexually active during treatment with PEMAZYRE and for 1 week after your last dose of PEMAZYRE.
  • are breastfeeding or plan to breastfeed. It is not known if PEMAZYRE passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of PEMAZYRE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of PEMAZYRE?

PEMAZYRE may cause serious side effects, including:

  • Eye problems. Certain eye problems are common with PEMAZYRE but can also be serious. Eye problems include dry eye or inflamed eyes, inflamed cornea (front part of the eye), increased tears, and a disorder of the retina (an internal part of the eye). You will need to see an eye specialist for a complete eye exam before you begin treatment with PEMAZYRE, every 2 months for the first 6 months, and then every 3 months during treatment with PEMAZYRE.
    • You should use artificial tears or substitutes, hydrating or lubricating eye gels as needed, to help prevent or treat dry eyes.
    • Tell your healthcare provider right away if you develop any changes in your vision during treatment with PEMAZYRE, including: blurred vision, flashes of light, or see black spots. You may need to see an eye specialist right away.
  • High phosphate levels in your blood (hyperphosphatemia) and buildup of minerals in different tissues in your body. Hyperphosphatemia is common with PEMAZYRE but can also be serious. High levels of phosphate in your blood may lead to buildup of minerals such as calcium, in different tissues in your body. Your healthcare provider will check your blood phosphate levels during treatment with PEMAZYRE.
    • Your healthcare provider may prescribe changes in your diet or phosphate lowering therapy, or change, interrupt, or stop PEMAZYRE if needed.
    • Tell your healthcare provider right away if you develop any muscle cramps, or numbness or tingling around your mouth.

The most common side effects of PEMAZYRE for cholangiocarcinoma include:

  • hair loss
  • diarrhea
  • nails separate from the bed or poor formation of the nail
  • feeling tired
  • change in sense of taste
  • nausea
  • constipation
  • mouth sores
  • dry eyes
  • dry mouth
  • decrease in appetite
  • vomiting
  • joint pain
  • stomach-area (abdominal) pain
  • low phosphate in blood
  • back pain
  • dry skin

The most common side effects of PEMAZYRE for myeloid/lymphoid neoplasms (MLN) include:

  • nails separate from the bed or poor formation of the nail
  • hair loss
  • mouth sores
  • diarrhea
  • dry eyes
  • tiredness
  • anemia
  • stomach-area (abdominal) pain
  • rash
  • constipation
  • dry mouth
  • nose bleeds
  • disorder of the retina
  • pain in feet or hands
  • decrease in appetite
  • dry skin
  • indigestion
  • back pain
  • nausea
  • blurry vision
  • swelling in feet, legs, hands, or arms
  • dizziness

These are not all the possible side effects of PEMAZYRE. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Keep PEMAZYRE and all medicines out of the reach of children.

General information about the safe and effective use of PEMAZYRE.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PEMAZYRE for a condition for which it is not prescribed. Do not give PEMAZYRE to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.

Please see the Full Prescribing Information for PEMAZYRE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.